Plesner, Torben http://orcid.org/0000-0002-2340-6068
Harrison, Simon J.
Quach, Hang
Lee, Cindy
Bryant, Adam
Vangsted, Annette
Estell, Jane
Delforge, Michel
Offner, Fritz
Twomey, Patrick
Choeurng, Voleak
Li, Junyi
Hendricks, Robert
Ruppert, Shannon M.
Sumiyoshi, Teiko
Miller, Karen
Cho, Eunpi
Schjesvold, Fredrik
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
https://doi.org/10.1007/s44228-022-00023-5
Funding for this research was provided by:
Genentech
Article History
Received: 25 August 2022
Accepted: 26 October 2022
First Online: 19 January 2023
Declarations
:
: TP was an advisor for Janssen, Celgene, Takeda, Oncopeptides, Genentech, CSL Behring and AbbVie; and received research support from Janssen, Genmab, Celgene, Takeda, Oncopeptides, Genentech, AbbVie and Roche. SH reports consultancy for Abbvie, Amgen, Celgene/Juno/BMS, Janssen Cilag, Novartis, Roche/Genentech, Haemalogix, Sanofi; research funding from Abbvie, Amgen, Celgene/Juno/BMS, Janssen Cilag, Novartis, Roche/Genentech, Haemalogix, Sanofi; honoraria from Abbvie, Amgen, Celgene/Juno/BMS, Janssen Cilag, Novartis, Roche/Genentech, Haemalogix, Sanofi; speakers bureau for Abbvie, Amgen, Celgene/Juno/BMS, Janssen Cilag, Novartis, Roche/Genentech; and advisory committee membership for Abbvie, Amgen, Celgene/Juno/BMS, Janssen Cilag, Novartis, Roche/Genentech, Haemalogix, Sanofi. HQ reports advisory committee membership for Amgen, Antengene, BeiGene, Celgene/ BMS, CSL Behring, Janssen Cilag, Karyopharm, Sanofi, Glaxo Smith Kline; research support from Amgen, Celgene/ BMS, Sanofi, Antengene, Karyopharm, Glaxo Smith Kline; honoraria from Abbvie, Amgen, Antengene, BeiGene, Celgene/ BMS, Janssen Cilag, Sanofi; and speakers bureau for Amgen, Abbvie, Antegenene, Celgene/BMS, Glaxo Smith Kline. CL was an advisor for Amgen, Janssen, BMS, Takeda, Antengene; and received research support from BMS. AB received honoraria from Amgen, Sandoz, Pfizer, Roche. AV, JE, MD, FO have nothing to disclose. PT, VC, JL, RH, SMP, TS, KM, and EC are employees of Genentech, Inc. and shareholders of F. Hoffmann La Roche, Ltd. FS receieved honoraria from Amgen, Takeda, Sanofi; consulting/advisory roles for Celgene, Janssen, Oncopeptides, Sanofi; and research funding from Celgene, Sanofi, Janssen, Oncopeptides, GSK.
: This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. Written informed consent was obtained from all patients prior to enrollment, in agreement with approved protocols from ethics committees at all study sites.
: Not applicable.